Locations:
November 18, 2026/Cancer

Spotting Ovarian Cancer Before it Starts

Inside Cleveland Clinic’s Quest for an Ovarian Cancer Screening Tool

Dr. Kevin Elias in the lab

Almost one million women in the U.S. are at elevated risk for developing ovarian cancer – and many are not aware of it. A simple blood test may one day change that.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Co-director of the Women's Cancer Research Program Kevin Elias, MD, and his research team developed a blood test designed to identify more than 95% of women with a predisposition to ovarian cancer – and to inform whether they are at risk of developing ovarian cancer in the near term. “Our vision is that in the future, this blood test will become part of routine screening for many women, much like a mammogram,” says Dr. Elias.

Background

The cure rate for ovarian cancer is greater than 90% when it’s found early, but there is no screening method for ovarian cancer. Most women who have early-stage ovarian cancer have normal bloodwork, and in roughly half of those with advanced-stage ovarian cancer, it doesn’t show up on an ultrasound.

Certain genetic tests can pinpoint increased cancer risk from mutations in some genes like BRCA1/BRCA2 but they don’t detect most inherited causes of ovarian cancer. “Women with a first-degree relative with ovarian cancer have a two to three times elevated risk of ovarian cancer, even if their own genetic test results are normal,” explains Dr. Elias.

Detecting early signs in the bloodstream

“The tricky part with ovarian cancer is that there really hasn't been a set of proteins that is made early enough by the cancer that you can detect it in the blood, nor is there enough of a marker that's been specific enough to ovarian cancer to help distinguish it from any number of non-cancerous conditions, much less other cancer types,” says Dr. Elias. Thus, instead of looking for protein markers of ovarian cancer, Elias’s lab studies microRNAs in the blood, since these change much earlier in the course of cancer development than proteins do.

Advertisement

These tiny strands of genetic material in the bloodstream may be a powerful means for earlier detection. MicroRNA changes occur months or even years before anything appears abnormal on a scan or a typical blood sample.

Launching a nationwide study

In 2019, Dr. Elias partnered with researchers at Dana-Farber Cancer Institute to launch the MicroRNA Detection (MiDE) Study, a nationwide trial evaluating the blood-based microRNA test for early detection of ovarian cancer in high-risk individuals. The researchers also believe microRNAs can help identify women at increased lifetime risk of ovarian cancer, even when genetic testing has been normal. This knowledge would help clinicians guide patients in deciding whether preventative interventions like surgery are appropriate – as well as the timing of these interventions.

“If a woman is at risk of ovarian cancer, she may choose to have her ovaries removed, but doing so has long-term health consequences as well as impacts on her reproductive health,” says Dr. Elias. “Women experiencing surgical menopause are at higher risk of cardiovascular disease, neurologic disease and bone fractures as they get older. In some cases, this procedure is warranted, but understanding when this is appropriate can reduce other health risks. The closer to menopause (or after menopause) that preventive surgeries occur, the fewer downstream sequelae there will be.

“If we know someone has a risk of ovarian cancer over the next 50 years, that’s not that helpful because it’s not actionable. If a patient is considering another pregnancy, for example, having a clear picture of the potential ovarian cancer risk over the next few years can help her with family planning decisions.”

Advertisement

Breaking down clinical trial barriers

The trial investigators set out to make the study as easy as possible for participants. Women from anywhere in the country can sign up for the trial directly, without requiring a physician referral. Once they’re enrolled in the study, the research coordinator arranges for a phlebotomist to go directly to the participant’s home to draw blood and then ship the samples to the research team for analysis.

“One of the reasons we’ve been successful at recruiting a broad group of individuals is that we’ve removed barriers, such as the need to travel, to participate in the trial,” says Dr. Elias. “This gives us greater confidence that the study outcomes will be generalizable.”

To date, more than 900 women across 46 states have enrolled in the study. The team’s goal is to enroll more than 2,000 women and report out initial findings within the next one to two years.

Key insights

“One of the real strengths of microRNAs is that they reflect the actual condition of the cells in the ovaries and the fallopian tubes and whether there are signs of cancer developing in them,” says Dr. Elias. Women may be up to 25 times more likely to develop ovarian cancer if their microRNA profile is positive.

The test delivers a probability score between 1 and 100 of the patient’s risk. To narrow down the time scale of that risk, researchers conduct serial blood tests over several years. The theory is that if the probability score remains stable, the chance of developing ovarian cancer in the near term is less. Conversely, researchers believe that the probability scores ticking up correlates with patients being more likely to develop ovarian cancer in the short term.

Advertisement

The team plans to validate these findings across the multi-year longitudinal study.

Early screening applications

In the short term, the first application of the microRNA test will likely be screening women at high risk of ovarian cancer due to a familial history of ovarian cancer, a personal genetic risk like BRCA1 or BRCA2 or having that genetic risk in her family. The test isn’t for women who already have ovarian cancer but for their family members who have an increased risk of contracting the disease.

Eventually, the aim is to have the test be generally available as a screening tool for all women. In the future, Dr. Elias envisions supplementing genetic assessments with microRNA testing, allowing for earlier intervention when the disease is in its most curable state.

What’s next

Once the researchers have analyzed cohorts from the observational MiDE study, they plan to transition to the ORBIT study where participants and their providers will receive their microRNA test results to guide early intervention and cancer prevention.

Advertisement

Related Articles

Dr. Anwer and colleagues
November 12, 2026/Cancer/Blood Cancers

FDA Approval of Iberdomide Marks Historic Milestone in Multiple Myeloma

CELMoD therapy receives approval based primarily on measurable residual disease

Dr. Dedousis
November 2, 2026/Cancer/Podcast

Expanding Germline Genetic Testing in Oncology (Podcast)

Are we missing patients?

Dr. Hanlee Chung
October 29, 2026/Cancer/Podcast

Redefining Resectability in Advanced Rectal Cancer (Podcast)

Expanding treatment options for patients with advanced and recurrent rectal cancer

Patient and healthcare providers
October 28, 2026/Cancer/Patient Support

Desire for Preventative Screening is Strong Among People Experiencing Homelessness

Study analyzes creative approaches to support people facing housing insecurity

AI tech
October 26, 2026/Cancer/Innovations

AI Task Force Develops Unified Strategy to Integrate Tech Innovations

Evaluating AI initiatives and their impact on operations and care delivery

DNA test
October 23, 2026/Cancer/News & Insight

Early Genetic Testing Linked to Bilateral Mastectomy in Young BRCA Carriers with Breast Cancer

Study reinforces the importance of genetic testing prior to local therapy decisions

Dr. Arun Singh
October 21, 2026/Cancer

Preserving Vision in Uveal Melanoma (Podcast)

Understanding expanding treatment options and potential advances

Patient and doctor
October 9, 2026/Cancer/News & Insight

First Radioligand Therapy Approved for Metastatic Hormone-Sensitive Prostate Cancer

Adding 177Lu-PSMA-617 to ADT plus an ARPI cut the risk of radiographic progression or mortality by 28%

Ad